Document:

EX-10.16

 Exhibit 10.16 

VIA HAND DELIVERY 
 July 10, 2019 (as amended
July 18, 2019 and sent via electronic mail) 
 Anthony Coyle 

Dear Tony: 
 As we discussed, your
employment with Pandion Therapeutics, Inc. (the “Company”) will end effective July 17, 2019 (the “Separation Date”). As we also discussed, the period between the date of this letter agreement and the Separation Date
will be a transition period, during which you will use your best efforts to, at the direction of the Company, professionally transition your duties, including cooperating with the Company’s announcement of your separation. Provided you do so,
you will be eligible to receive the severance benefits described in paragraph 2 below if you sign and return this letter agreement to me by August 1, 2019 (but no earlier than the Separation Date) and do not revoke your acceptance (as described
below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below,
including the release of claims set forth in paragraph 4. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days
to do so. If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it (the “Revocation Period”) by notifying me in writing. If you do not so
revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the Revocation Period. 

Although your receipt of the severance benefits is expressly conditioned on your entering into this letter agreement, the following will apply
regardless of whether or not you timely enter into this letter agreement: 
  

	 	•	 	 As of the Separation Date, all salary payments from the Company will cease and any benefits you had as of the
Separation Date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law. 

  

	 	•	 	 You will receive on the Separation Date payment for your final wages and any unused vacation time accrued through
the Separation Date. 

  

	 	•	 	 You may, if eligible and at your own cost, elect to continue receiving group medical insurance pursuant to the
“COBRA” law. Please consult the COBRA materials to be provided under separate cover for details regarding these benefits. 

  

	 	•	 	 You are obligated to keep confidential and not to use or disclose any and all
non-public information concerning the Company that you acquired during the course of your employment with the Company, including any non-public information concerning
the Company’s business affairs, business prospects, and financial condition, except as otherwise permitted by paragraph 11 below. Further, you remain subject to your continuing obligations to the Company as set forth in the Invention and
Non-Disclosure and Non-Competition and Non-Solicitation Agreements you previously executed for the benefit of the Company,
which remain in full force and effect. 

  

	 	•	 	 You must return to the Company on the Separation Date all Company property. 

 The following numbered paragraphs set forth the terms and conditions that will apply if you
timely sign and return this letter agreement and do not revoke your acceptance: 
 1.    Resignations
– You hereby resign, effective as of the Separation Date, from any and all positions that you hold as an officer and/or director of the Company, its subsidiaries, or parent, including, without limitation, your positions as a President and
Treasurer, and as a member of the Board of Directors, of the Company, Pandion Programco 1, Inc., and Pandion Therapeutics Holdco, LLC, and agree that you will execute and deliver any documents reasonably necessary to effectuate such resignations.

 2.    Severance Benefits –The Company will provide you with the following severance benefits (the
“severance benefits”): 
  

	 	a.	 Severance Pay. The Company will pay to you $420,784, less all applicable taxes and withholdings, as
severance pay (an amount equivalent to twelve (12) months of your current base salary). This severance pay will be paid in installments in accordance with the Company’s regular payroll practices, but in no event shall payments begin
earlier than the Company’s first payroll date following expiration of the Revocation Period. 

  

	 	b.	 COBRA Benefits. Should you timely elect and be eligible to continue receiving group health insurance
pursuant to the “COBRA” law, the Company will, for twelve (12) months following the Separation Date (the “COBRA Contribution Period”), continue to pay the share of the premiums for such coverage to the same extent it was
paying such premiums on your behalf immediately prior to the Separation Date. The remaining balance of any premium costs during the COBRA Contribution Period, and all premium costs thereafter, shall be paid by you on a monthly basis for as long as,
and to the extent that, you remain eligible for COBRA continuation. 

 You will not be eligible for, nor
shall you have a right to receive, any payments or benefits from the Company following the Separation Date other than as set forth in this paragraph. 

3.    Equity – As of the Separation Date, you hold 2,000,000 Common Shares of Pandion Therapeutics
Holdco LLC (the “Total Shares”), 958,326 of which are vested based on your vesting commencement date of August 1, 2017 (the “Vested Shares”). Pandion Therapeutics Holdco LLC intends to repurchase from you, in accordance with
the terms of the Restricted Common Share Agreement dated January 1, 2019, an aggregate of 1,041,674 Common Shares, which amount constitutes the number of Total Shares that are not Vested Shares as of the Separation Date (the
“Unvested Shares”). You hereby acknowledge and agree that (i) the Vested Shares constitute all equity rights you have in the Company, its subsidiaries, or parent, and (ii) Pandion Therapeutics Holdco LLC has advised you of
its intention to repurchase the Unvested Shares, which it will accomplish within ninety (90) days following the Separation Date in accordance with the terms set forth in the Restricted Common Share Agreement. 

4.    Release of Claims – In consideration of the severance benefits, which you acknowledge you would
not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective
past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate

  
 - 2 - 

 
capacities) (collectively, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs,
accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that you ever had or now have
against any or all of the Released Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims
under Title VII of the Civil Rights Act, the Americans With Disabilities Act, the Age Discrimination in Employment Act, the Genetic Information Nondiscrimination Act, the Family and Medical Leave Act, the Worker Adjustment and Retraining
Notification Act, the Rehabilitation Act, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, and the Employee Retirement Income Security Act, all as amended; all claims arising out of the Massachusetts Fair Employment
Practices Act, Mass. Gen. Laws ch. 151B, § 1 et seq., the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 et seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil
Rights Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102, Mass. Gen. Laws ch. 214, § 1C (Massachusetts right to be free from sexual harassment law), the Massachusetts
Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the
Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud,
wrongful discharge, and breach of contract (including, without limitation, all claims arising under or relating to your May 8, 2017 offer letter); all claims to any non-vested ownership interest in the
Company, contractual or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation)
under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that this release of claims does not prevent you from filing a charge with, cooperating with, or participating in
any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such charge,
investigation, or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys’ fees or other remedial relief in connection with any such charge, investigation or proceeding). 

5.    Continuing Obligations – You acknowledge and reaffirm your confidentiality and non-disclosure obligations discussed on page 1 of this letter agreement, as well as the obligations set forth in the Invention and Non-Disclosure and Non-Competition and Non-Solicitation Agreements, which survive your separation from employment with the Company. 

6.    Non-Disparagement – You understand and agree that, to the
extent permitted by law and except as otherwise permitted by paragraph 11 below, you will not, in public or private, make any false, disparaging, derogatory or defamatory statements, online (including, without limitation, on any social media,
networking, or employer review site) or otherwise, to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the
Company, regarding the Company or any of the other Released Parties, or regarding the Company’s business affairs, business prospects, or financial condition. The Company, in turn, agrees to instruct those with knowledge of this letter agreement
not to, in public or private, make any false, disparaging, derogatory or defamatory statements about you. 

  
 - 3 - 

 7.    Company Affiliation – You agree that, following
the Separation Date, you will not hold yourself out as an officer, employee, or otherwise as a representative of the Company, its subsidiaries or parent.

8.    Return of Company Property – You confirm that you have returned to the Company all keys,
files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, flash drives and other storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any
other property of the Company, its subsidiaries or parent in your possession or control, and that you have left intact all, and have otherwise not destroyed, deleted, or made inaccessible, any electronic documents, including, but not limited to,
those that you developed or helped to develop during your employment, and that you have not (a) retained any copies in any form or media; (b) maintained access to any copies in any form, media, or location; (c) stored any copies in
any physical or electronic locations that are not readily accessible or not known to the Company or that remain accessible to you; or (d) sent, given, or made accessible any copies to any persons or entities that the Company has not authorized
to receive such electronic or hard copies. You further confirm that you have cancelled all accounts for your benefit, if any, in the Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts,
and computer accounts. 
 9.    Business Expenses and Final Compensation – You acknowledge that you
have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you. You further acknowledge that you have received payment in full for all
services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses, and accrued, unused vacation time, and that no other compensation is owed to you except as provided herein. 

10.    Confidentiality – You understand and agree that, to the extent permitted by law and except as
otherwise permitted by paragraph 11 below, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and
representatives and shall not be disclosed except as otherwise agreed to in writing by the Company. 

11.    Scope of Disclosure Restrictions – Nothing in this letter agreement or elsewhere prohibits you
from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies, filing a complaint with government agencies, or participating in government agency
investigations or proceedings. You are not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information you obtained through a communication that was subject to the
attorney-client privilege. Further, notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: “An individual shall not be held criminally or civilly liable
under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely
for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for
retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document
containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.” 

  
 - 4 - 

 12.    Cooperation – You agree that, to
the extent permitted by law, you shall cooperate fully with the Company, its subsidiaries and parent in the investigation, defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be
brought in the future against the Company, its subsidiaries or parent by a third party or by or on behalf of the Company, its subsidiaries or parent against any third party, whether before a state or federal court, any state or federal government
agency, or a mediator or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel for the Company, its subsidiaries or parent, at reasonable times and
locations designated by the Company, its subsidiaries or parent, to investigate or prepare the claims or defenses of the Company, its subsidiaries or parent, to prepare for trial or discovery or an administrative hearing, mediation, arbitration or
other proceeding and to act as a witness when requested by the Company, its subsidiaries or parent. You further agree that, to the extent permitted by law, you will notify the Company promptly in the event that you are served with a subpoena
(other than a subpoena issued by a government agency), or in the event that you are asked to provide a third party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company,
its subsidiaries or parent. 
 13.    Amendment and Waiver – This letter agreement shall be
binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto. This letter agreement is binding upon and shall
inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or
any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

14.    Validity – Should any provision of this letter agreement be declared or be determined by any
court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter
agreement. 
 15.    Nature of Agreement – You understand and agree that this letter agreement
is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company, its subsidiaries or parent. 

16.    Acknowledgments – You acknowledge that you have been given at least twenty-one (21) days to consider this letter agreement, and that the Company is hereby advising you to consult with an attorney of your own choosing prior to signing this letter agreement. You acknowledge that
the changes made to the initial July 10, 2019 letter agreement were made at your request and that such changes, whether material or immaterial, did not restart the twenty-one (21) day review period.
You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this
seven (7) day revocation period. You understand and agree that by entering into this letter agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers
Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled. 

17.    Voluntary Assent – You affirm that no other promises or agreements of any kind have been
made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement. You further state and represent that you have carefully read this
letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act. 

  
 - 5 - 

 18.    Applicable Law – This letter agreement shall
be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of
Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising
out of, under or in connection with this letter agreement or the subject matter hereof. 
 19.    Entire
Agreement – This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels all
previous oral and written negotiations, agreements, and commitments in connection therewith.  
 20.    Tax
Acknowledgement – In connection with the severance benefits provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be
responsible for all applicable taxes with respect to such severance benefits under applicable law. You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the severance
benefits set forth in paragraph 2 of this letter agreement. 
 If you have any questions about the matters covered in this letter agreement,
please call me. 
  

			
	Very truly yours,
		
	By:	 	/s/ Alan Crane
		 	 Alan Crane
 Chairman of the
Board

 I hereby agree to the terms and conditions set forth above. I have been given at least
twenty-one (21) days to consider this letter agreement, and I have chosen to execute this on the date below. I acknowledge that the changes made to the initial July 10, 2019 letter agreement were
made at my request and that such changes, whether material or immaterial, did not restart the twenty-one (21) day review period. I intend that this letter agreement will become a binding agreement between
me and the Company if I do not revoke my acceptance in seven (7) days. 
  

					
	/s/ Anthony Coyle	 		 	07/23/2019
	Anthony Coyle	 		 	Date

 To be returned in a timely manner as set forth on the first page of this letter agreement. 

  
 - 6 -EX-10.17

 Exhibit 10.17 

IMMUNOTOLERANCE, INC. 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”), made this 27th day of
March, 2017 is entered into by Immunotolerance, Inc., a Delaware corporation (the “Company”), and Alan Crane, an individual (the “Consultant”). 

WHEREAS, the Company and the Consultant desire to establish the terms and conditions under which the Consultant will provide services to the
Company. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows: 
 1.
Services. The Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably requested from time to time by the Company, including, but not limited to, the services specified on
Schedule A to this Agreement. The Consultant also agrees to provide the Company with related services that may be requested from time to time by the Company. During the Consultation Period (as defined below) and for a period of one year
thereafter, except in connection with his performance of the Services, the Consultant shall not engage in any activity in the field described on Schedule A to this Agreement, and he shall not assist any other person or organization that
engages in any such activity. 
 2. Term. This Agreement shall commence on the Effective Date and shall continue until the four-year
anniversary of the Effective Date (such period, as it may be extended, either by the mutual written agreement of the parties or automatically, or earlier terminated being referred to as the “Consultation Period”), unless sooner
terminated in accordance with the provisions of Section 4, and shall automatically renew for successive one-year periods, unless the Company provides 90 days’ notice of termination before any such
successive period. 
 3. Compensation. 

3.1 Shares. In connection with the execution of this Agreement, Consultant and Company shall enter into a Restricted Stock Agreement.
Subject to approval of the Board of Directors of the Company, the Company shall issue and sell to the Consultant, and the Consultant shall purchase from the Company, subject to the terms and conditions set forth in this Agreement and the Restricted
Stock Agreement, 1,990,000 shares (the “Shares”) of common stock, $0.0001 par value, of the Company (“Common Stock”), at a purchase price of $0.0001 per share, for an aggregate purchase price of $190. Such Shares are in addition
to the 10,000 shares of Common Stock held by the Consultant as of the date hereof. The Consultant agrees that the Shares shall be subject to the terms of the Restricted Stock Agreement. 

3.2 Expenses. The Company shall reimburse the Consultant for all reasonable and necessary documented out of pocket expenses incurred or
paid by the Consultant in connection with, or related to, the performance of Consultant’s services under this Agreement. 

 The Consultant shall submit to the Company itemized monthly statements, in a form satisfactory to the
Company, of such expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within thirty (30) days after receipt thereof. 

3.3 Benefits. The Consultant shall not be entitled to any benefits, coverages or privileges, including, without limitation, health
insurance, social security, unemployment, medical or pension payments, made available to employees of the Company. 
 4. Termination.
The Company may terminate the Consultation Period at any time for Cause (as defined below). In the event of such termination, the Consultant shall be entitled to payment hereunder and for expenses paid or incurred prior to the effective date of
termination. Such payments shall constitute full settlement of any and all claims of the Consultant of every description against the Company. Notwithstanding the foregoing, the Company may terminate the Consultation Period effective immediately upon
receipt of written notice by the Consultant, if the Consultant breaches or threatens to breach any provision of Section 6. For purposes of this Section 4, “Cause” shall exist in the event of (i) a good faith finding by the
Board of Directors of the Company (A) of repeated and willful failure of the Consultant after written notice to perform his reasonable Services for the Company, or (B) that the Consultant has engaged in dishonesty, gross negligence or
misconduct; or (ii) the conviction of the Consultant of, or the entry of a pleading of guilty or nolo contendere by the Consultant to, any crime involving moral turpitude or any felony. The Consultant may terminate the Consultation Period at
any time upon thirty (30) days’ written notice. 
 5. Cooperation. The Consultant shall use Consultant’s best efforts
in the performance of Consultant’s obligations under this Agreement. The Company shall provide such access to its information and property as may be reasonably required in order to permit the Consultant to perform Consultant’s obligations
hereunder. The Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety
of persons and property. 
 6. Proprietary Information and Inventions. 

6.1 Proprietary Information. 

(a) The Consultant acknowledges that Consultant’s relationship with the Company is one of high trust and confidence and that in the
course of Consultant’s service to the Company, Consultant will have access to and contact with Proprietary Information. The Consultant will not disclose any Proprietary Information to any person or entity other than employees of the Company or
use the same for any purposes (other than in the performance of the services) without written approval by an officer of the Company, either during or after the Consultation Period, unless and until such Proprietary Information has become public
knowledge without fault by the Consultant. 

  
 - 2 - 

 (b) For purposes of this Agreement, Proprietary Information shall mean, by way of
illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential nature, owned, possessed or used by the Company, concerning the
Company’s business, business relationships or financial affairs, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical or
research data, clinical data, know-how, computer program, software, software documentation, hardware design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments,
marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant
in the course of Consultant’s service as a consultant to the Company. 
 (c) The Consultant’s obligations under this
Section 6.1 shall not apply to any information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.1, (ii) is generally disclosed to
third parties by the Company without restriction on such third parties, or (iii) is approved for release by written authorization of an officer of the Company. 

(d) The Consultant agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory
notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Consultant or others, which shall come into
Consultant’s custody or possession, shall be and are the exclusive property of the Company to be used by the Consultant only in the performance of Consultant’s duties for the Company and shall not be copied or removed from the Company
premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Consultant shall be delivered to the Company, upon the earlier of
(i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Consultant shall not retain any such materials or copies thereof or any such tangible property. 

(e) The Consultant agrees that Consultant’s obligation not to disclose or to use information and materials of the types set forth in
paragraphs (b) and (d) above, and Consultant’s obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or
suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Consultant. 
 (f) The
Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the
course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions that are known to Consultant and to take all action necessary to discharge the
obligations of the Company under such agreements. 

  
 - 3 - 

 6.2 Inventions. 

(a) All inventions, ideas, creations, discoveries, computer programs, works of authorship, data, developments, technology, designs,
innovations and improvements (whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others or under
Consultant’s direction and whether during normal business hours or otherwise, (i) during the Consultation Period if related to the business of the Company or (ii) during or after the Consultation Period if resulting or directly
derived from Proprietary Information (as defined above) (collectively under clauses (i) and (ii), “Inventions”), shall be the sole property of the Company. The Consultant hereby assigns to the Company all Inventions and any and
all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as Consultant’s duly
authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or
planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Consultant not during normal working hours, not on the Company’s premises and not using
the Company’s tools, devices, equipment or Proprietary Information. The Consultant further acknowledges that each original work of authorship which is made by the Consultant (solely or jointly with others) within the scope of this Agreement and
which is protectable by copyright is a “work made for hire,” as that term is defined in the United States Copyright Act. 
 (b)
The Consultant agrees that if, in the course of performing the Services, the Consultant incorporates into any Invention developed under this Agreement any preexisting invention, improvement, development, concept, discovery or other proprietary
information owned by the Consultant or in which the Consultant has an interest (“Prior Inventions”), (i) the Consultant will inform the Company, in writing before incorporating such Prior Inventions into any Invention, and
(ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, transferable worldwide license with the right to grant and authorize sublicenses, to make, have made, modify, use, import, offer for sale, sell, reproduce,
distribute, modify, adapt, prepare derivative works of, display, perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection with such Invention, and to practice any method
related thereto. The Consultant will not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any Invention without the Company’s prior written permission. 

(c) Upon the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments, documents and
other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any
foreign country with respect to any Invention. The Consultant also hereby waives all claims to moral rights in any Inventions. 
 (d) The
Consultant shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual
reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times. 

  
 - 4 - 

 7. Non-Solicitation. During the Consultation
Period and for a period of one year thereafter, the Consultant shall not, either alone or in association with others, (i) solicit, or permit any organization directly or indirectly controlled by the Consultant to solicit, any employee of the
Company to leave the employ of the Company; or (ii) solicit for employment, hire or engage as an independent contractor, or permit any organization directly or indirectly controlled by the Consultant to solicit for employment, hire or engage as
an independent contractor, any person who is employed or engaged by the Company; provided, that this clause (ii) shall not apply to any individual whose employment with the Company has been terminated for a period of six months or
longer. 
 8. Other Agreements; Warranty. 

8.1 The Consultant hereby represents that, except as the Consultant has disclosed in writing to the Company, the Consultant is not bound by the
terms of any agreement with any third party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of Consultant’s consultancy with the Company, to refrain from competing, directly or
indirectly, with the business of such third party or to refrain from soliciting employees, customers or suppliers of such third party. The Consultant further represents that Consultant’s performance of all the terms of this Agreement and the
performance of the services as a consultant of the Company do not and will not breach any agreement with any third party to which the Consultant is a party (including, without limitation, any nondisclosure or
non-competition agreement), and that the Consultant will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any current or previous
employer or others. 
 8.2 The Consultant hereby represents, warrants and covenants that Consultant has the skills and experience necessary
to perform the services, that Consultant will perform said services in a professional, competent and timely manner, that Consultant has the power to enter into this Agreement and that Consultant’s performance hereunder will not infringe upon or
violate the rights of any third party or violate any federal, state or municipal laws. 
 9. Independent Contractor Status. 

9.1 The Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of
the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 

9.2 The Consultant shall have the right to control and determine the time, place, methods, manner and means of performing the services. In
performing the services, the amount of time devoted by the Consultant on any given day will be entirely within the Consultant’s control, and the Company will rely on the Consultant to put in the amount of time necessary to fulfill the
requirements of this Agreement. The Consultant will provide all equipment and supplies required to perform the services. The Consultant is not required to attend regular meetings at the Company. However, upon reasonable notice, the Consultant shall
meet with representatives of the Company at a location to be designated by the parties to this Agreement. 

  
 - 5 - 

 9.3 In the performance of the services, the Consultant has the authority to control and
direct the performance of the details of the services, the Company being interested only in the results obtained. However, the services contemplated by the Agreement must meet the Company’s standards and approval and shall be subject to the
Company’s general right of inspection and supervision to secure their satisfactory completion. 
 9.4 The Consultant shall not use the
Company’s trade names, trademarks, service names or service marks without the prior approval of the Company. 
 9.5 The Consultant shall
be solely responsible for all state and federal income taxes, unemployment insurance and social security taxes in connection with this Agreement and for maintaining adequate workers’ compensation insurance coverage. 

10. Remedies. The Consultant acknowledges that any breach of the provisions of Section 1, 6 or 7 of this Agreement shall result in
serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that, in addition to any other remedy the Company may have, the Company shall be
entitled to enforce the specific performance of this Agreement by the Consultant and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond. 

11. Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal
delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other
in accordance with this Section 11. 
 12. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall
include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

13. Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and
understandings, whether written or oral, relating to the subject matter of this Agreement. 
 14. Amendment. This Agreement may be
amended or modified only by a written instrument executed by both the Company and the Consultant. 
 15.
Non-Assignability of Contract. This Agreement is personal to the Consultant and the Consultant shall not have the right to assign any of Consultant’s rights or delegate any of Consultant’s
duties without the express written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be
void and shall constitute a breach and a default by the Consultant. 

  
 - 6 - 

 16. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

17. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective
successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall not be assigned
by Consultant. 
 18. Interpretation. If any restriction set forth in Section 1, 6 or 7 is found by any court of competent
jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities
or geographic area as to which it may be enforceable. 
 19. Survival. The last sentence of Section 1 and Sections 4 through 20
shall survive the expiration or termination of this Agreement. 
 20. Miscellaneous. 

20.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

20.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement. 
 20.3 In the event that any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

[Remainder of Page Intentionally Left Blank] 

  
 - 7 - 

 IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the
date and year first above written. 
  

					
	COMPANY:
	
	IMMUNOTOLERANCE, INC.
		
	By:	 	 /s/ Dan Matloff

		 	Name:	 	Dan Matloff
		 	Title:	 	CFO
	
	CONSULTANT:
	
	 /s/ Alan Crane

	Name: Alan Crane

 SIGNATURE PAGE TO CONSULTING AGREEMENT 

 SCHEDULE A 

Consultant will provide advice and services to the Company as requested by the Board of Directors from time to time. The field for purposes of
Section 1 is defined as drugs and cell-based therapies designed for tissue-specific immunosuppression.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]